Literature DB >> 22541247

Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus.

Luisa Lunardon, Aimee S Payne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22541247      PMCID： PMC3412073          DOI： 10.1016/j.jaci.2012.03.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Authors:  A Razzaque Ahmed; Zachary Spigelman; Lisa A Cavacini; Marshall R Posner
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

2.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Authors:  Dedee F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis Diaz; David Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David Rubenstein; Hiroshi Shimizu; Animesh A Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2008-03-14       Impact factor: 11.527

3.  Immunogenicity of rituximab in patients with severe pemphigus.

Authors:  Enno Schmidt; Kirsten Hennig; Christian Mengede; Detlef Zillikens; Arno Kromminga
Journal:  Clin Immunol       Date:  2009-06-07       Impact factor: 3.969

4.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

Authors:  J Pijpe; G W van Imhoff; F K L Spijkervet; J L N Roodenburg; G J Wolbink; K Mansour; A Vissink; C G M Kallenberg; H Bootsma
Journal:  Arthritis Rheum       Date:  2005-09

5.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

Authors:  Wen-Kai Weng; Ronald Levy
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

6.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

7.  A single cycle of rituximab for the treatment of severe pemphigus.

Authors:  Pascal Joly; Hugo Mouquet; Jean-Claude Roujeau; Michel D'Incan; Danièle Gilbert; Serge Jacquot; Marie-Lise Gougeon; Christophe Bedane; Ralf Muller; Brigitte Dreno; Marie-Sylvie Doutre; Emmanuel Delaporte; Christine Pauwels; Nathalie Franck; Frédéric Caux; Catherine Picard; Emmanuelle Tancrede-Bohin; Philippe Bernard; François Tron; Michael Hertl; Philippe Musette
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

8.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.

Authors:  D Albert; J Dunham; S Khan; J Stansberry; S Kolasinski; D Tsai; S Pullman-Mooar; F Barnack; C Striebich; R J Looney; E T Luning Prak; R Kimberly; Y Zhang; R Eisenberg
Journal:  Ann Rheum Dis       Date:  2008-02-04       Impact factor: 19.103

9.  Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.

Authors:  Shoko Goto; Hiroaki Goto; Reo Tanoshima; Hiromi Kato; Hiroyuki Takahashi; Osamu Sekiguchi; Sumio Kai
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.319
  9 in total
  11 in total

1.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 2.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 3.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

4.  Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.

Authors:  Christoph T Ellebrecht; Eun J Choi; David M Allman; Donald E Tsai; William A Wegener; David M Goldenberg; Aimee S Payne
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

Review 5.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

Review 6.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

7.  Development of antirituximab antibodies in children with nephrotic syndrome.

Authors:  Yo Han Ahn; Hee Gyung Kang; Jiwon M Lee; Hyun Jin Choi; Il-Soo Ha; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2014-03-12       Impact factor: 3.714

8.  Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.

Authors:  Christine Lebrun; Mikael Cohen; Maria Alessandra Rosenthal-Allieri; Saskia Bresch; Sylvia Benzaken; Romain Marignier; Barbara Seitz-Polski; Michel Ticchioni
Journal:  Neurol Ther       Date:  2018-06-07

Review 9.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

10.  Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice.

Authors:  Yuki Moritoki; Koichi Tsuneyama; Yuka Nakamura; Kentaro Kikuchi; Akira Shiota; Yoshiyuki Ohsugi; Zhe-Xiong Lian; Weici Zhang; Guo-Xiang Yang; Shigeharu Ueki; Masahide Takeda; Ayumi Omokawa; Tomoo Saga; Akiko Saga; Daisuke Watanabe; Masahito Miura; Yoshiyuki Ueno; Patrick S C Leung; Atsushi Tanaka; M Eric Gershwin; Makoto Hirokawa
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.